Purchase this article with an account.
Jung Woo Byun, Sena Hwang, Chan Woo Kang, Jin Hee Kim, Min Kyung Chae, Jin Sook Yoon, Eun Jig Lee; Therapeutic Effect of Protocatechuic Aldehyde in an In Vitro Model of Graves' Orbitopathy. Invest. Ophthalmol. Vis. Sci. 2016;57(10):4055-4062. doi: 10.1167/iovs.15-19037.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Protocatechuic aldehyde (3,4-dihydroxybenzaldehyde; PCA) is extracted from Salvia miltiorrhiza, and has been reported to possess antiproliferative, antioxidant, and antiadipogenesis properties in various in vivo and in vitro experiments. This study aimed to outline the antioxidant and suppressive effects of PCA on adipogenesis and hyaluronan production in orbital fibroblasts to help with designing therapeutic approaches for Graves' orbitopathy (GO).
We assessed the in vitro effects of PCA on orbital fibroblasts, which were cultured from orbital fat tissue obtained from patients undergoing orbital decompression for severe GO. Control tissue was obtained from patients undergoing orbital surgery with no history of GO or Graves' hyperthyroidism.
The 2,2-diphenyl-1-picrylhydrazyl and 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt assay results confirmed the free radical scavenging effect of PCA after treatment. Protocatechuic aldehyde exhibited a suppressive effect on intracellular reactive oxygen species generation and upregulated heme oxygenase-1 expression in Western blot analysis. Protocatechuic aldehyde attenuated TNF-α and IL-1β–induced hyaluronan production. Oil Red-O staining results revealed a decrease in lipid droplets and suppressed expression of the adipogenesis-related proteins peroxisome proliferator-activated receptor (PPAR)–γ, CCAAT/enhancer binding protein (c/EBP)-α, and c/EBP-β upon treatment with PCA during adipose differentiation.
In this study, PCA exerted significant antioxidant and antiadipogenic effects and inhibited the production of hyaluronan in GO orbital fibroblasts. Accordingly, PCA potentially could be used as a novel treatment option for GO.
This PDF is available to Subscribers Only